Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)

被引：0
|
作者：
Govindarajan, R.
Siegel, E.
Makhoul, I.
Williamson, S.
机构：
[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15557
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma
    Govindarajan, Rangaswamy
    Siegel, Eric
    Makhoul, Issam
    Williamson, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (03): : 254 - 257
  • [2] A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC).
    Sachdev, Jasgit C.
    Javed, Ahmed Y.
    Weir, Alva Bowen
    Korn, Ronald I.
    Gulla, Shannon M.
    Newbold, Ronald G.
    Smeltzer, Matthew
    Osarogiagbon, Raymond U.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Karwal, Mark
    Verslype, Chris
    Van Vlierberghe, Hans
    Kardosh, Adel
    Zagonel, Vittorina
    Stal, Per
    Sarker, Debashis
    Palmer, Daniel H.
    Vogel, Arndt
    Edeline, Julien
    Cattan, Stephane
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Chisamore, Michael Jon
    Wang Anran
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
    Hsu, C-H.
    Lee, M. S.
    Lee, K-H.
    Numata, K.
    Stein, S.
    Verret, W.
    Hack, S.
    Spahn, J.
    Liu, B.
    Huang, C.
    He, R.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
    Lee, M.
    Ryoo, B-Y.
    Hsu, C-H.
    Numata, K.
    Stein, S.
    Verret, W.
    Hack, S.
    Spahn, J.
    Liu, B.
    Abdullah, H.
    He, R.
    Lee, K-H.
    ANNALS OF ONCOLOGY, 2019, 30 : 875 - 875
  • [6] Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC)
    Kaseb, A. O.
    Iwasaki, M.
    Javle, M.
    Onicescu, G.
    Garrett-Mayer, E.
    Abbruzzese, J. L.
    Thomas, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma
    Jonasch, E.
    Tsavachdidou, D.
    Wood, C. G.
    Matin, S. F.
    Corn, P. G.
    Tamboli, P.
    Wang, X.
    Tannir, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
    Sun, W.
    Haller, D. G.
    Mykulowycz, K.
    Rosen, M.
    Soulen, M.
    Capparo, M.
    Faust, T.
    Giantonia, B.
    Olthoff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
    Kaseb, A. O.
    Garrett-Mayer, E.
    Morris, J. S.
    Xiao, L.
    Lin, E.
    Onicescu, G.
    Hassan, M. M.
    Hassabo, H. M.
    Iwasaki, M.
    Deaton, F. L.
    Abbruzzese, J. L.
    Thomas, M. B.
    ONCOLOGY, 2012, 82 (02) : 67 - 74
  • [10] Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
    He, A. R. R.
    Numata, K.
    Lee, K-H.
    Hsu, C-H.
    Lee, J.
    Morimoto, M.
    Verret, W.
    Hack, S. P.
    Spahn, J.
    Liu, B.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S690 - S690
12345